Opdivo has received Breakthrough Therapy Designation from FDA for advanced urothelial carcinoma
The FDA ( Food and Drug Administration ) has granted Breakthrough Therapy Designation to Opdivo ( Nivolumab ) for the potential indication of unresectable locally advanced or metastatic urothelial car ...
read article